Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	New Amedeo service: Amedeo COVID-19 (formerly 2019-nCoV) Weekly publication summary

Prostate Cancer

Free Subscription 20.01.2020 4 AJR Am J Roentgenol 2 BMC Urol 1 Br J Cancer 1 Br J Radiol 1 Cancer Res 3 Clin Cancer Res 2 Eur Urol 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 2 J Nucl Med 10 J Urol 2 JAMA 2 Lancet Oncol 9 Nat Rev Urol 1 Oncogene 1 PLoS One 1 Proc Natl Acad Sci U S A 1 Prog Urol 7 Prostate 15 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. ROBERTSON MS, Sakellis CG, Hyun H, Jacene HA, et al
   Extraprostatic Uptake of (18)F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer.
   AJR Am J Roentgenol. 2020 Jan 15:1-8. doi: 10.2214/AJR.19.21894.
   PubMed     Text format     Abstract available
   
   
2. OSMANY S, Zaheer S, Bartel TB, Johnston M, et al
   Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers.
   AJR Am J Roentgenol. 2019 Jun 5:1-14. doi: 10.2214/AJR.19.21084.
   PubMed     Text format     Abstract available
   
   
3. GIGANTI F, Rosenkrantz AB, Villeirs G, Panebianco V, et al
   The Evolution of MRI of the Prostate: The Past, the Present, and the Future.
   AJR Am J Roentgenol. 2019 Apr 30:1-13. doi: 10.2214/AJR.18.20796.
   PubMed     Text format     Abstract available
   
   
4. MEERMEIER NP, Foster BR, Liu JJ, Amling CL, et al
   Impact of Direct MRI-Guided Biopsy of the Prostate on Clinical Management.
   AJR Am J Roentgenol. 2019 Apr 1:1-6. doi: 10.2214/AJR.18.21009.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

5. HOLZE S, Mende M, Healy KV, Koehler N, et al
   Comparison of various continence definitions in a large group of patients undergoing radical prostatectomy: a multicentre, prospective study.
   BMC Urol. 2019;19:70.
   PubMed     Text format     Abstract available
   
   
6. DING XF, Huang TB, Lu SM, Tao HZ, et al
   Pelvic plexus block to provide better anesthesia in transperineal template-guided prostate biopsy: a randomised controlled trial.
   BMC Urol. 2019;19:63.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

7. EL-KENAWI A, Gatenbee C, Robertson-Tessi M, Bravo R, et al
   Correction: Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer.
   Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0710.
   PubMed     Text format     Abstract available
   
   

   
   Br J Radiol

8. KEENAN L, Ibrahim N, Dunne MT, Finn M, et al
   The effect of anaemia on normal tissue toxicity and survival outcomes in prostate cancer treated with radical radiotherapy and neo-adjuvant androgen deprivation.
   Br J Radiol. 2020 Jan 16:20190577. doi: 10.1259/bjr.20190577.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

9. NESSLER I, Khera E, Vance S, Kopp A, et al
   Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models.
   Cancer Res. 2020 Jan 15. pii: 0008-5472.CAN-19-2295.
   PubMed     Text format     Abstract available
   
   

   
   Clin Cancer Res

10. CORN PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, et al
    A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jan 15. pii: 1078-0432.CCR-19-2389.
    PubMed     Text format     Abstract available
    
    
11. AGARWAL N, Nussenzveig RH, Hahn AW, Hoffman JM, et al
    Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2591.
    PubMed     Text format     Abstract available
    
    
12. LI Y, Yang R, Henzler CM, Ho Y, et al
    Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jan 13. pii: 1078-0432.CCR-19-3023.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

13. LIN DW, Shih MC, Aronson W, Basler J, et al
    Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study.
    Eur Urol. 2020 Jan 7. pii: S0302-2838(19)30964.
    PubMed     Text format     Abstract available
    
    
14. CHIN J, Bauman G, Power N, Ward A, et al
    The Singularity is Near(ish): Emerging Applications of Artificial Intelligence in Prostate Cancer Management.
    Eur Urol. 2020 Jan 8. pii: S0302-2838(19)30945.
    PubMed     Text format    
    
    

    
    Int J Radiat Oncol Biol Phys

15. TENDULKAR RD, Mian OY
    Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable.
    Int J Radiat Oncol Biol Phys. 2020;106:238.
    PubMed     Text format    
    
    

    
    J Clin Oncol

16. TRABULSI EJ, Rumble RB, Jadvar H, Hope T, et al
    Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Jan 15:JCO1902757. doi: 10.1200/JCO.19.02757.
    PubMed     Text format     Abstract available
    
    

    
    J Nucl Med

17. JANSEN BHE, Cysouw MCF, Vis AN, van Moorselaar RJA, et al
    Repeatability of Quantitative (18)F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
    J Nucl Med. 2020 Jan 10. pii: jnumed.119.236075. doi: 10.2967/jnumed.119.236075.
    PubMed     Text format     Abstract available
    
    
18. SONNI I, Eiber M, Fendler WP, Alano RM, et al
    Impact of (68)Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single Center Study.
    J Nucl Med. 2020 Jan 10. pii: jnumed.119.237602. doi: 10.2967/jnumed.119.237602.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

19. TANEJA SS
    Re: Risk of Prostate Cancer for Men Fathering through Assisted Reproduction: Nationwide Population Based Register Study.
    J Urol. 2020 Jan 13:101097JU000000000000073002.
    PubMed     Text format    
    
    
20. TANEJA SS
    Re: Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    J Urol. 2020 Jan 13:101097JU000000000000073001.
    PubMed     Text format    
    
    
21. ELLIOTT S
    Re: Salvage Brachytherapy for Locally-Recurrent Prostate Cancer after Radiation Therapy: A Comparison of Efficacy and Toxicity Outcomes with High-Dose Rate and Low-Dose Rate Brachytherapy.
    J Urol. 2020 Jan 13:101097JU000000000000074501.
    PubMed     Text format    
    
    
22. HUBER PM, Afzal N, Arya M, Boxler S, et al
    PSA Criteria to Diagnose Failure of Cancer Control following Focal Therapy for Non-metastatic Prostate Cancer Using High Intensity Focused Ultrasound.
    J Urol. 2020 Jan 13:101097JU0000000000000747. doi: 10.1097/JU.0000000000000747.
    PubMed     Text format     Abstract available
    
    
23. SATKUNASIVAM R, Miles BJ
    Editorial Comment.
    J Urol. 2020;203:329.
    PubMed     Text format    
    
    
24. PERLIS N
    Editorial Comment.
    J Urol. 2020;203:329.
    PubMed     Text format    
    
    
25. ATALA A
    Re: The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
    J Urol. 2020 Jan 13:101097JU000000000000073201.
    PubMed     Text format    
    
    
26. ATALA A
    Re: Selective Targeting of PARP-2 Inhibits Androgen Receptor Signaling and Prostate Cancer Growth through Disruption of FOXA1 Function.
    J Urol. 2020 Jan 13:101097JU0000000000000732. doi: 10.1097/JU.0000000000000732.
    PubMed     Text format    
    
    
27. TANEJA SS
    Re: Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
    J Urol. 2020;203:252-253.
    PubMed     Text format    
    
    
28. CADEDDU JA
    Re: Robot-Assisted Radical Prostatectomy after Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence.
    J Urol. 2020;203:233.
    PubMed     Text format    
    
    

    
    JAMA

29. HOFFMAN KE, Penson DF, Zhao Z, Huang LC, et al
    Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    JAMA. 2020;323:149-163.
    PubMed     Text format     Abstract available
    
    
30. PARSONS JK, Zahrieh D, Mohler JL, Paskett E, et al
    Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    JAMA. 2020;323:140-148.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

31. BULTEN W, Pinckaers H, van Boven H, Vink R, et al
    Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study.
    Lancet Oncol. 2020 Jan 8. pii: S1470-2045(19)30739.
    PubMed     Text format     Abstract available
    
    
32. STROM P, Kartasalo K, Olsson H, Solorzano L, et al
    Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.
    Lancet Oncol. 2020 Jan 8. pii: S1470-2045(19)30738.
    PubMed     Text format     Abstract available
    
    

    
    Nat Rev Urol

33. THOMA C
    Mechanisms of high-dose testosterone.
    Nat Rev Urol. 2019 Jul 11. pii: 10.1038/s41585-019-0216.
    PubMed     Text format    
    
    
34. SIVA S, Udovicich C, Tran B, Zargar H, et al
    Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
    Nat Rev Urol. 2020 Jan 14. pii: 10.1038/s41585-019-0272.
    PubMed     Text format     Abstract available
    
    
35. FENNER A
    Equal access = equal outcomes in black and white men.
    Nat Rev Urol. 2019;16:447.
    PubMed     Text format    
    
    
36. FENNER A
    AVPR1A: a target in CRPC?
    Nat Rev Urol. 2019;16:508.
    PubMed     Text format    
    
    
37. STONE L
    AR - the link between transcription and translation.
    Nat Rev Urol. 2019;16:565.
    PubMed     Text format    
    
    
38. THOMA C
    Prostate tumour pH affects macrophage function.
    Nat Rev Urol. 2019;16:566-567.
    PubMed     Text format    
    
    
39. MARCH B, Faulkner S, Jobling P, Steigler A, et al
    Tumour innervation and neurosignalling in prostate cancer.
    Nat Rev Urol. 2020 Jan 14. pii: 10.1038/s41585-019-0274.
    PubMed     Text format     Abstract available
    
    
40. STONE L
    An adaptive approach to therapy.
    Nat Rev Urol. 2019;16:388.
    PubMed     Text format    
    
    
41. BRADLEY CA
    (68)Ga-PSMA-11 PET enables accurate detection of recurrent disease.
    Nat Rev Urol. 2019;16:388.
    PubMed     Text format    
    
    

    
    Oncogene

42. LEMPIAINEN JK, Manjur ABMK, Malinen M, Ketola K, et al
    BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation.
    Oncogene. 2020 Jan 10. pii: 10.1038/s41388-020-1153.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

43. PICKLES K, Kazda L, Barratt A, McGeechan K, et al
    Evaluating two decision aids for Australian men supporting informed decisions about prostate cancer screening: A randomised controlled trial.
    PLoS One. 2020;15:e0227304.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

44. HSU EC, Rice MA, Bermudez A, Marques FJG, et al
    Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
    Proc Natl Acad Sci U S A. 2020 Jan 13. pii: 1905384117.
    PubMed     Text format     Abstract available
    
    

    
    Prog Urol

45. ANDRIANNE R
    The "Mini-Jupette" sling at the time of inflatable penile prosthesis implantation: Adequate treatment for erectile dysfunction with mild incontinence and/or climacturia after radical prostatectomy.
    Prog Urol. 2019 Jul 9. pii: S1166-7087(19)30112.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

46. TEPLY BA, Qiu F, Antonarakis ES, Carducci MA, et al
    Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
    Prostate. 2019;79:929-933.
    PubMed     Text format     Abstract available
    
    
47. METZGER AL, Abel S, Wegner RE, Fuhrer R, et al
    Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.
    Prostate. 2019;79:1457-1461.
    PubMed     Text format     Abstract available
    
    
48. KRANZBUHLER B, Salemi S, Umbricht CA, Deberle LM, et al
    Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of (177) Lu-PSMA-617 in LNCaP cells.
    Prostate. 2019;79:1450-1456.
    PubMed     Text format     Abstract available
    
    
49. MIYAZAWA Y, Sekine Y, Shimizu N, Takezawa Y, et al
    An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
    Prostate. 2019;79:1462-1470.
    PubMed     Text format     Abstract available
    
    
50. ANDREWS JR, Ahmed ME, Karnes RJ, Kwon E, et al
    Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
    Prostate. 2020 Jan 13. doi: 10.1002/pros.23954.
    PubMed     Text format     Abstract available
    
    
51. KIM S, Yang X, Yin A, Zha J, et al
    Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.
    Prostate. 2019;79:896-908.
    PubMed     Text format     Abstract available
    
    
52. BAUMANN B, Lugli G, Gao S, Zenner M, et al
    High levels of PIWI-interacting RNAs are present in the small RNA landscape of prostate epithelium from vitamin D clinical trial specimens.
    Prostate. 2019;79:840-855.
    PubMed     Text format     Abstract available
    
    

    
    Urology

53. ALVES LJ, Gameiro CD, Lopes SP, Ascensao JB, et al
    Prostate Leiomyosarcoma: A Rare Misleading Tumor.
    Urology. 2019;130:13-16.
    PubMed     Text format     Abstract available
    
    
54. SHELTON JB, Paivanas TA, Buffington P, Ruyle SR, et al
    Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States.
    Urology. 2019;130:72-78.
    PubMed     Text format     Abstract available
    
    
55. DAI C, Ganesan V, Nyame YA, Almassi N, et al
    Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance.
    Urology. 2019;130:106-112.
    PubMed     Text format     Abstract available
    
    
56. CARAM MEV, Kaufman SR, Modi PK, Herrel L, et al
    Adoption of Abiraterone and Enzalutamide by Urologists.
    Urology. 2019;131:176-183.
    PubMed     Text format     Abstract available
    
    
57. KAZMI Z, Sulaiman N, Shaukat M, Rafi A, et al
    Atypical Presentation of Seminoma in the Prostate - Case Report.
    Urology. 2019;132:33-36.
    PubMed     Text format    
    
    
58. BALAKRISHNAN AS, Zhao S, Cowan JE, Broering JM, et al
    Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor.
    Urology. 2019;131:157-165.
    PubMed     Text format     Abstract available
    
    
59. JACOBS BL, Yabes JG, Lopa SH, Heron DE, et al
    The development and validation of prostate cancer-specific physician-hospital networks.
    Urology. 2020 Jan 13. pii: S0090-4295(20)30012.
    PubMed     Text format     Abstract available
    
    
60. ALSHAK MN, Patel N, Gross MD, Margolis D, et al
    Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy.
    Urology. 2020;135:117-123.
    PubMed     Text format     Abstract available
    
    
61. SETIA S, Feng C, Coogan C, Vourganti S, et al
    Urology Residents' Experience With Simulation: Initial Evaluation of MRI/US Fusion Biopsy Workshop.
    Urology. 2019;134:51-55.
    PubMed     Text format     Abstract available
    
    
62. HARPER SN, Hale LP, Ferrandino MN, Moul JW, et al
    Acute Presentation of Previously Unrecognized Congenital Ureteropelvic Junction Obstruction 5 Weeks After Radical Retropubic Prostatectomy.
    Urology. 2020;135:20-23.
    PubMed     Text format    
    
    
63. LLORENS DE KNECHT E, Guadarrama Vega S, Donate G, Palou Redorta J, et al
    Robot-assisted Radical Prostatectomy Due to a Primary Carcinoid Prostatic Tumor in a Three-Year-Old Child: A Case Report.
    Urology. 2019;133:216-218.
    PubMed     Text format     Abstract available
    
    
64. TRABULSI EJ, Calio BP, Kamel SI, Gomella LG, et al
    Prostate Contrast Enhanced Transrectal Ultrasound Evaluation of the Prostate With Whole-Mount Prostatectomy Correlation.
    Urology. 2019;133:187-191.
    PubMed     Text format     Abstract available
    
    
65. KAIHO Y, Ito J, Iwamura H, Anan G, et al
    Nerves in the Areas Posterior to the Prostate Base Contribute to Erectile Function: An Intraoperative Electrical Stimulation Assessment.
    Urology. 2019;132:156-160.
    PubMed     Text format     Abstract available
    
    
66. LEONG JY, Chandrasekar T, Sebastiano C, Rshaidat H, et al
    Prostatic Stromal Tumors of Uncertain Malignant Potential.
    Urology. 2019;132:e3-e4.
    PubMed     Text format     Abstract available
    
    
67. HENNING GM, Vetter JM, Drake BF, Ippolito JE, et al
    Diagnostic Performance of Prostate Multiparametric Magnetic Resonance Imaging in African-American Men.
    Urology. 2019;134:181-185.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: